Tumor Infiltrating Lymphocytes Global Market Report 2023: Sector to Reach $15.56 Billion by 2027 at a 13.7% CAGR
23. Mai 2023 04:53 ET
|
Research and Markets
Dublin, May 23, 2023 (GLOBE NEWSWIRE) -- The "Tumor Infiltrating Lymphocytes Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global tumor infiltrating...
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
18. April 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by SanofiMechanism of Action of Tiziana’s first-in-class, only...
CD3 Antibodies Clinical Trials Market Size Companies Insight
21. März 2023 04:27 ET
|
KuicK Research
Delhi, March 21, 2023 (GLOBE NEWSWIRE) -- Antibodies have transformed cancer treatment because of their flexible properties that allow them to be used as both antagonists and agonists. With the...
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
16. Juni 2021 07:30 ET
|
MacroGenics, Inc.
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific moleculesMacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific...
Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies
01. Oktober 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced today that their investigational new drug application (IND) for TNB-486, a bispecific...